The genericization of most psychotropic medicine, the ''patent cliff'' experienced by many blockbuster psychiatric medicines, and the lack of reimbursement by public/private payers has contributed to a lack of enthusiasm for drug development for psychiatric disorders.
This foregoing confluence of factors could, however, provide the impetus for a different approach to drug discovery and development. 
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